Biolux Logo

Biolux Research announces new clinical trial to evaluate use of photobiomodulation during clear aligner orthodontic treatment

April 24, 2014
Vancouver-based Biolux Research is preparing to commercialize a new product for dramatically reducing the timeline for orthodontic treatment. A new clinical trial will evaluate the efficacy of combining Biolux-developed and proprietary photobiomodulation technology with clear aligners during orthodontic treatment. 
Biolux Research, developer of Light Accelerated Orthodontics™ technology and products, is pleased to announce the start of a new clinical trial to evaluate the efficacy of combining Biolux-developed and proprietary photobiomodulation technology with clear aligners during orthodontic treatment. Clear aligners are an alternate approach to orthodontic treatment, and are growing in popularity because of the cosmetic benefit as compared to traditional brackets and wires. By combining clear aligners and the intraoral Biolux technology to move teeth faster, patients may be able to achieve both the cosmetic benefit and significant reductions in treatment timeline. The Biolux technology includes a soft silicone intraoral tray with embedded photobiomodulation technology, which the patient takes home and self-treats with a short daily treatment.

The study will be conducted at the Department of Orthodontics, University of Alabama at Birmingham, USA, by principal investigator, Chung How Kau, BDS, MScD, MBA, PhD, MOrth, FDS, FFD (Ortho), FAMS (Ortho), Cert (Ortho). The purpose of this clinical trial is to prospectively investigate the effect of photobiomodulation on the treatment timeline of patients undergoing orthodontic treatment with clear aligners, compared to a control group with only clear aligner treatment. The total patient population is 40 subjects, divided equally into treated and control groups. Patients will be recruited and treated at Department of Orthodontics at University of Alabama. Treatment progress and completion will be evaluated using thePAR (Peer Assessment Rating) index as well as the Index of Complexity, Outcome and Need (ICON). The study has already received ethics approval, and enrollment has started.

“Biolux has invested heavily over the past few years to investigate and prove out the efficacy of our photobiomodulation technology and products, with a range of clinical studies and case series, and we are excited to start a formal study on the combination of our technology and clear aligners at UAB,” states Peter Brawn, DDS, founder and chief scientific officer of Biolux Research. “The OrthoPulse™ product, which is nearing regulatory approvals and commercial launch, is designed to be safely used with any form of orthodontic mechanics, and we are keen to show that combining our technology with clear aligners could lead to a significant solution for the patient to address both the timeline and cosmetic concerns. We believe that while the industry is focusing on optimizing the mechanics of tooth movement, our technology will optimize the biology of tooth movement, leading to patients achieving great smiles faster.”

About Biolux Research
Biolux Research is a world leader in the development of innovative Light Accelerated Orthodontics™ technology and products for use in orthodontics, implantology, and other dentistry markets. Biolux focuses on product development and clinical research, and its proprietary, patent-pending technologies have been developed to enhance clinical outcomes and dramatically reduce treatment timelines in orthodontics and dentistry in a safe, effective and noninvasive approach.